Physician profile
Peter H Ko
NPI 1730145012
$6,784.62
in general payments reported to CMS, 2019-2025
48 companies · $1,004 in 2025
The $1,004 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $834 · 2020: $709 · 2021: $1,076 · 2022: $632 · 2023: $1,253 · 2024: $1,275 · 2025: $1,004.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,533.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,532.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $873.79 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $679.76 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $668.73 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $563.20 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novartis Pharmaceuticals Corporation | $500.75 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $445.94 | 2019-2025 | Jardiance, Ofev, Spiriva Respimat |
| Abbott Laboratories | $306.49 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Glaxosmithkline, LLC. | $289.49 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $277.16 | 2019-2025 | Evenity, Repatha, Prolia |
| Merck Sharp & Dohme LLC | $228.93 | 2019-2024 | Gardasil, Capvaxive, Gardasil 9 |
| Pfizer INC. | $208.73 | 2021-2025 | |
| Xeris Pharmaceuticals, INC. | $195.26 | 2023-2024 | Gvoke Hypopen |
| Biohaven Pharmaceutical Holding Company Ltd. | $174.47 | 2022 | |
| Allergan, INC. | $162.05 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $105.72 | 2019-2022 |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Ko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.